0HNC Stock Chart & Stats
$61.33
-$0.48(-0.78%)
At close: 4:00 PM EDT
$61.33
-$0.48(-0.78%)
Day’s Range― - ―
52-Week Range$49.39 - $65.92
Previous CloseN/A
Volume212.00
Average Volume (3M)460.00
Market Cap
$11.60B
Enterprise Value$10.39K
Total Cash (Recent Filing)$874.00M
Total Debt (Recent Filing)$4.20B
Price to Earnings (P/E)42.9
Beta1.09
Next Earnings
Nov 03, 2026EPS Estimate
1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.38
Shares Outstanding193,284,440
10 Day Avg. Volume298
30 Day Avg. Volume460
Financial Highlights & Ratios
PEG Ratio-1.71
Price to Book (P/B)1.87
Price to Sales (P/S)3.54
P/FCF Ratio15.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$89.40Price Target Upside45.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)4.94
Revenue Forecast (FY)$3.87B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & Low LeverageConsistent trailing free cash flow and a conservative debt-to-equity ratio provide durable financial flexibility. This cash base supports sustained R&D, commercial investment, M&A integration and capital spending, reducing refinancing risk and enabling multi-year execution of growth plans.
Expanded, Diversified Commercial Portfolio (Amicus)The Amicus deal materially diversifies BioMarin’s revenue mix beyond core enzyme therapies, adding near-term commercial products with peak potential. Integration can lift scale, reduce per-unit costs, and broaden payer relationships, improving revenue durability and growth optionality over the medium term.
Durable Demand And Regulatory Progress For VoxzogoStrong patient growth, extensive long-term safety/efficacy data and an accepted FDA sNDA materially increase the probability of full approval and label expansion. A larger approved addressable market and durable clinical evidence underpin sustained uptake and lower commercial risk over coming years.
Bears Say
Weakened Profitability And ReturnsDespite high gross margins, a sharp compression in operating and net margins has materially reduced returns on equity. This weakens the company's ability to convert revenue growth into sustainable shareholder returns and raises sensitivity to margin pressure from competition, pricing or costs.
Manufacturing Reliability RiskA failed process qualification that triggered a material one-time charge highlights execution risk in biologics manufacturing. Repeated or larger-scale manufacturing issues could raise COGS, constrain supply for launches, force outsourcing and erode margins and commercial momentum over the medium term.
Regulatory And Competitive UncertaintiesOngoing IP litigation and new competitive entry into achondroplasia create downside risk to protected revenues and pricing power. Together these factors can reduce market share and future pricing leverage, increasing volatility in revenue conversion and long-term margin sustainability.
BioMarin Pharmaceutical News
0HNC FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest share price was $49.39 and its highest was $65.92 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $11.60B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Nov 03, 2026 which is in 87 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Aug 06, 2026. The company reported $1.2 earnings per share for the quarter, beating the consensus estimate of $0.945 by $0.255.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on BioMarin Pharmaceutical dividends here
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 1.42.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 193,284,440 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $1.2 in its last earnings report, beating expectations of $0.945. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in GB:0HNC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.40 (45.77% Upside)
$89.40 (45.77% Upside)
Blogger Sentiment
Bullish
GB:0HNC Sentiment 71%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $176.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.20%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
0HNC Company Deck
0HNC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook driven by the recent Amicus acquisition, upgraded 2026 revenue guidance (~20% total revenue growth and ~30% Enzyme Therapies growth at midpoint), strong underlying patient demand (Voxzogo patients +20% y/y; Enzyme Therapies +6% y/y), and multiple near‑term clinical catalysts. Near‑term softness in reported Q1 revenue, a $31M one‑time manufacturing charge, higher operating expenses and modest 2026 EPS dilution are notable headwinds, but management attributes much of the revenue softness to order timing and positions acquisition dilution as temporary with accretion expected within 12 months and substantial accretion in 2027. Overall, the positives (deal, guidance lift, patient growth, pipeline milestones) outweigh the one‑time charges and timing issues.View all GB:0HNC earnings summaries0HNC Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
0HNC Stock 12 Month Forecast
Average Price Target
$89.40
▲(45.77% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Summit Therapeutics
―
Immunovant
―